



# Loxo Oncology to Present at Upcoming Investor Conferences

November 7, 2017

STAMFORD, Conn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will be participating in the following upcoming investor conferences:

- Stifel 2017 Healthcare Conference on November 14, 2017, in New York City. At 2:45 p.m. ET Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview.
- Evercore ISI Biopharma Catalyst/Deep Dive Conference on November 30, 2017, in Boston. At 4:35 p.m. ET Joshua H. Bilenker, M.D., chief executive officer, and Jacob S. Van Naarden, chief business officer, will be participating in a fireside chat.

Live webcasts of the presentation and fireside chat will be available at <https://ir.loxooncology.com/>. A replay of each webcast will be available on the company's website for 30 days.

## About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at [www.loxooncology.com](http://www.loxooncology.com).

## Contacts for Loxo Oncology, Inc.

Company:

Jacob S. Van Naarden  
Chief Business Officer  
[jake@loxooncology.com](mailto:jake@loxooncology.com)

Investors:

Peter Rahmer  
The Trout Group, LLC  
646-378-2973  
[prahmer@troutgroup.com](mailto:prahmer@troutgroup.com)

Media:

Dan Budwick  
1AB Media  
973-271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)

Loxo Oncology, Inc.